SCHEMBL1103316

SCHEMBL1103316

CC1(C)c2ccccc2N(c2c3ccccc3c(N3c4ccccc4C(C)(C)c4ccccc43)c3c2cnc2ccccc23)c2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.35
AR P10275 1/20 0.34
PIK3CA P42336 1/20 0.33
KDM4E B2RXH2 2/20 0.33
GPR3 P46089 1/20 0.33
TLR7 Q9NYK1 2/20 0.32
CDK4 P11802 1/20 0.32
CCND1 P24385 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
GAA P10253 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
TOP2A P11388 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
MPO P05164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103432 0.88 TLR7 (0.36) PDPK1ARPIK3CAKDM4ETLR7
SCHEMBL1103611 0.84 MEN1 (0.37) PDPK1KDM4EGPR3CDK4CCND1
SCHEMBL1103551 0.82 MET (0.37) PDPK1PIK3CAKDM4EGPR3TLR7
SCHEMBL1103313 0.81 CDK4 (0.36) PDPK1KDM4EGPR3TLR7CDK4
SCHEMBL13231596 0.81 KMT2A (0.42) KDM4EKMT2AMEN1MAPTGAA
SCHEMBL1103328 0.79 ADORA3 (0.38) KDM4EGPR3TLR7MAPTGAA
SCHEMBL1103323 0.79 MPO (0.35) PDPK1KDM4EGPR3MPOLMNA
SCHEMBL1103312 0.79 KDM4E (0.35) PDPK1KDM4EGPR3TLR7CDK4
SCHEMBL1103321 0.79 MPO (0.35) PDPK1KDM4EGPR3TLR7CDK4
SCHEMBL1103326 0.78 TLR7 (0.35) PDPK1KDM4EGPR3TLR7PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 PDPK1 3594/4885AR 2779/4885PIK3CA 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.